Journal article
A phase I‐II trial of 4'‐deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia
Clinical pharmacology and therapeutics, Vol.45(4), pp.424-428
04/1989
DOI: 10.1038/clpt.1989.50
PMID: 2702800
Abstract
In a phase I‐II study, 21 patients with relapsed or refractory acute leukemia were treated with 4'‐deoxydoxorubicin (esorubicin), the 4'‐deoxy derivative of doxorubicin. Four of 14 evaluable patients with acute nonlymphocytic leukemia (ANLL) in relapse or refractory to other anthracyclines achieved partial response (28.5%). Pharmacokinetics were similar to those of the parent compound, doxorubicin. Esorubicin has activity in ANLL and has pharmacologic properties comparable to those of other anthracyclines. Dose‐limiting toxicity occurs in the form of mucositis, which may limit its use in combination with other antileukemic drugs.
Clinical Pharmacology and Therapeutics (1989) 45, 424–428; doi:10.1038/clpt.1989.50
Details
- Title: Subtitle
- A phase I‐II trial of 4'‐deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia
- Creators
- Janice P Dutcher - Albert Einstein Cancer Center/Montefiore Medical CenterCharles E Riggs - University of IowaJanice J Strauman - Albert Einstein Cancer Center/Montefiore Medical CenterBrian Link - University of IowaPeter H Wiernik - Albert Einstein Cancer Center/Montefiore Medical Center
- Resource Type
- Journal article
- Publication Details
- Clinical pharmacology and therapeutics, Vol.45(4), pp.424-428
- DOI
- 10.1038/clpt.1989.50
- PMID
- 2702800
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- Number of pages
- 5
- Grant note
- Cancer Center Core (P30CA1130) Veterans Administration Oncology Merit Review Award
- Language
- English
- Date published
- 04/1989
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094759902771
Metrics
23 Record Views